Item 2.02. Results of Operations and
Financial Condition.
As discussed below, in connection with its participation in the
41st Annual J.P. Morgan Healthcare Conference beginning on January
9th, 2023, Agile Therapeutics, Inc. (the “Company”) updated its
corporate presentation to include disclosure that the Company
expects fourth quarter 2022 Twirla factory sales to be
approximately 43,200 total cycles and full year 2022 Twirla factory
sales to be approximately 113,600 total cycles. The updated
presentation also includes disclosure that the Company expects full
year 2023 net revenue to be in the range of $25 million to $30
million and that operating expenses are expected to remain similar
to the second half of 2022.
Because the Company’s financial statements for the quarter and year
ended December 31, 2022 have not yet been finalized or audited,
this preliminary statement regarding the Company’s factory sales
for the quarter and year ended December 31, 2022 is subject to
change, and the Company’s actual factory sales during these periods
may differ materially from these preliminary estimates.
Accordingly, you should not place undue reliance on these
preliminary estimates.
Item 7.01.Regulation FD
Disclosure.
The information set forth in Item 2.02 of this Current Report on
Form 8-K (this “Report”) is incorporated into this Item 7.01 by
reference.
Beginning on January 9, 2023, the Company will participate in the
41st Annual J.P. Morgan Healthcare Conference in San Francisco,
California. The Company has updated its corporate presentation to
include the above-disclosed information for use at investor
conferences, including the J.P. Morgan Healthcare Conference.
In addition, on January 9, 2023, the Company issued a press release
providing similar information to the updates provided in its
corporate presentation.
A copy of the Company’s updated corporate presentation is attached
hereto as Exhibit 99.1 and a copy of the press release is attached
hereto as Exhibit 99.2.
In accordance with General Instructions B.2 and B.6 of Form 8-K,
the information included in Items 2.02 and 7.01 of this Report,
including Exhibits 99.1 and 99.2 hereto, shall not be deemed
“filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference into any filing made by the Company under
the Exchange Act or the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such a
filing.
Item 9.01.
Financial Statements and
Exhibits.
(d)
Exhibits.